GlassScriptPhysician profile
Carol Ann Goodman
NPI 1629052386
$122,522.09
in general payments reported to CMS, 2019-2025
45 companies · $271 in 2025
The $271 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,839 · 2020: $1,081 · 2021: $20K · 2022: $74K · 2023: $16K · 2024: $10K · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Food and Beverage: $1,779.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,537.42 |
| Food and Beverage | $1,778.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $89,648.41 | 2019-2022 | |
| Abbvie INC. | $25,166.56 | 2019-2025 | |
| Merz North America, INC. | $2,907.31 | 2019-2023 | Xeomin |
| Glaxosmithkline, LLC. | $1,008.63 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $641.84 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $538.70 | 2019-2023 | Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $259.86 | 2019-2025 | Airsupra, Farxiga |
| Merck Sharp & Dohme LLC | $208.67 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $194.29 | 2019-2024 | |
| Lilly USA, LLC | $193.50 | 2019-2025 | Zepbound |
| Janssen Pharmaceuticals, INC | $185.36 | 2021-2023 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $142.83 | 2019-2022 | |
| Astellas Pharma US INC | $141.16 | 2019-2023 | Veozah |
| Pfizer INC. | $137.13 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $115.00 | 2021-2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Goodman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.